|Other Names||Apoptosis-inducing factor 3, 1---, Apoptosis-inducing factor-like protein, AIFM3, AIFL|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP9174b was selected from the C-term region of human AIFM3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Induces apoptosis through a caspase dependent pathway. Reduces mitochondrial membrane potential.|
|Cellular Location||Mitochondrion. Note=Does not translocate to the nucleus upon induction of apoptosis|
|Tissue Location||Ubiquitous. Expressed in bone marrow, cerebral cortex, liver, ovary, thymus, thyroid gland and tongue (at protein level).|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This protein encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3' mRNA processing factors with actively-transcribed chromatin. Mutations in this gene have been linked to hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma.
Vierimaa,O., et.al., J. Endocrinol. Invest. 32 (6), 512-518 (2009)Hahn,M.A., et.al., J. Endocrinol. 201 (3), 387-396 (2009)
If you have any additional inquiries please email technical services at email@example.com.